JPRN-UMIN000005534尚未招募2 期
Randomized Phase II trial of Palonosetron/Dexamethasone concurrent therapy with prevention of CINV according to chemotherapy including Oxaliplatin or Irinotecan in patients with advanced colorectal cancer. - Randomized Phase II trial of Palonosetron/Dexamethasone concurrent therapy with prevention of CINV according to chemotherapy including Oxaliplatin or Irinotecan in patients with advanced colorectal cancer. (PALODEX-C)
ara Hospital Kinki University Faculty of Medicine0 个研究点目标入组 80 人开始时间: 2011年5月9日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Severe complications (2) Obstraction of the gastric outlet or bowel (3) Symptomatic brain metastases (4) Massive pleural or abdominal effusion (5) Nervous tic (6) Hypersensitivity or severe drug allergy for 5-HT3RA (7) Hypersensitivity or severe drug allergy for dexamethasone. (8) Serious drug hypersensitivity (9) Emetic episodes or CTCAE grade 2< or = nausea (10) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. (11) Any other cases who are regarded as inadequate for study enrollmet by investigators
研究者
相似试验
已完成
不适用
A phase II trial of palonosetron and 1-day dexamethasone and 3-day aprepitant to prevent nausea and vomiting in patients receiving paclitaxel and carboplatipatients receiving paclitaxel and carboplatin for gynecologic malignanciesJPRN-UMIN000013082ara Medical University70
已完成
2 期
A phase II trial of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer.gynecological cancerJPRN-UMIN000011857Kansai Clinical Oncology Group (KCOG)40
已完成
2 期
Randomized Phase II trial of palonosetron, aprepitant plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by chemotherapy for breast cancerbreast cancerJPRN-UMIN000006977Kitasato University School of Medicine Department of Surgery80
已完成
3 期
A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)Colorectal CancerJPRN-UMIN000013249HOPE group(Hokkaido Supportive Care Oncology Project - an Expert Group Initiative)320
终止
2 期
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With BevacizumabBrain CancerNCT00636805Duke University63